vidaza

Generic: azacitidine

Labeler: celgene corporation
NDC Directory HUMAN PRESCRIPTION DRUG NDA Inactive Finished

Drug Facts

Product Profile

Brand Name vidaza
Generic Name azacitidine
Labeler celgene corporation
Dosage Form INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
Routes
INTRAVENOUS SUBCUTANEOUS
Active Ingredients

azacitidine 100 mg/1

Manufacturer
Celgene Corporation

Identifiers & Regulatory

Product NDC 59572-102
Product ID 59572-102_8cba79e2-11fa-4eb9-87e7-827ca781fbf3
Product Type HUMAN PRESCRIPTION DRUG
Marketing Category NDA
Application Number NDA050794
Listing Expiration 2026-12-31
Marketing Start 2004-07-05

Pharmacologic Class

Established (EPC)
nucleoside metabolic inhibitor [epc]
Mechanism of Action
nucleic acid synthesis inhibitors [moa]

Normalized Code Variants

Searchable formats for this product NDC code

Digits Only 59572102
Hyphenated Format 59572-102

Supplemental Identifiers

RxCUI
485246 545206
UNII
M801H13NRU
NUI
N0000000233 N0000175595

Packaging Origin

Original Packager
true

Resolved Product View

Precedence rule: structured NDC data is preferred, falling back to linked label metadata when unavailable. Source tags show the origin of each value.

Resolved Identity

Brand Name vidaza (source: ndc)
Generic Name azacitidine (source: ndc)
Application Number NDA050794 (source: ndc)
Routes
INTRAVENOUS SUBCUTANEOUS
source: ndc

Resolved Composition

Strengths
  • 100 mg/1
source: ndc
Packaging
  • 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 CARTON (59572-102-01)
source: ndc

Packages (1)

59572-102-01 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 CARTON (59572-102-01)

Ingredients (1)

azacitidine (100 mg/1)

Linked Drug Pages (1)

VIDAZA ndc-match (0.9)

Raw FDA Data

View complete raw FDA NDC JSON payload 
{"route": ["INTRAVENOUS", "SUBCUTANEOUS"], "spl_id": "8cba79e2-11fa-4eb9-87e7-827ca781fbf3", "openfda": {"nui": ["N0000000233", "N0000175595"], "unii": ["M801H13NRU"], "rxcui": ["485246", "545206"], "spl_set_id": ["3495a71a-cc04-4776-851f-f185956f32af"], "pharm_class_epc": ["Nucleoside Metabolic Inhibitor [EPC]"], "pharm_class_moa": ["Nucleic Acid Synthesis Inhibitors [MoA]"], "manufacturer_name": ["Celgene Corporation"], "is_original_packager": [true]}, "finished": true, "packaging": [{"sample": false, "description": "1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 CARTON (59572-102-01)", "package_ndc": "59572-102-01", "marketing_start_date": "20040705"}], "brand_name": "VIDAZA", "product_id": "59572-102_8cba79e2-11fa-4eb9-87e7-827ca781fbf3", "dosage_form": "INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION", "pharm_class": ["Nucleic Acid Synthesis Inhibitors [MoA]", "Nucleoside Metabolic Inhibitor [EPC]"], "product_ndc": "59572-102", "generic_name": "azacitidine", "labeler_name": "Celgene Corporation", "product_type": "HUMAN PRESCRIPTION DRUG", "brand_name_base": "VIDAZA", "active_ingredients": [{"name": "AZACITIDINE", "strength": "100 mg/1"}], "application_number": "NDA050794", "marketing_category": "NDA", "marketing_start_date": "20040705", "listing_expiration_date": "20261231"}